 |
About TPG Biotech
|
TPG Biotechnology, a leading science-based investor, leverages deep technical expertise, sector experience, and the global TPG footprint to invest in five thematic areas: Drug Discovery and Development, Allied Pharmaceutical Services, Cleantech, Personalized Medicine and Medical Devices. TPG Biotech uses a risk-balanced approach to portfolio construction, sourcing transactions from both the scientific and venture communities, then leveraging our team's scientific experience to develop the differential scientific insights that are a hallmark of our track record.
Some recent investments include Aerie (therapeutics for opthalmic disease), Nodality (personalized medicine), ShangPharma (China-based CRO), and Virobay (anti-viral discovery and development). Our unique mix of sector interests has also led to two Biotech/Tech convergence opportunities: Amyris (cleantech, biotech) and Agria (Ag Bio, Cleantech). For a list of TPG's representative Biotech investments, click here.
|
|
|
|
|
